Modulation pharmacologique de la radiosensibilité tumorale des mélanomes par inhibition de MEK

by Schick, Ulrike
Published 2015

Uveitis as a Result of MAP Kinase Pathway Inhibition

by Lavnish Joshi, Andreas Karydis, Maria Gemenetzi, Emily H. Shao, Simon R.J. Taylor
Published 2013-11-01

Inhibition of ISG15 Enhances the Anti-Cancer Effect of Trametinib in Colon Cancer Cells

by Zhou S, Ren M, Xu H, Xia H, Tang Q, Liu M
Published 2019-11-01

Durable Complete Response of a Recurrent Mesencephalic Glioblastoma Treated with Trametinib and Low-Dose Dabrafenib in a Patient with Neurofibromatosis Type 1

by Gil Awada, Daphne Serruys, Julia Katharina Schwarze, Lien Van De Voorde, Johnny Duerinck, Bart Neyns
Published 2020-09-01

Unusual Skin Carcinomas Induced by BRAF Inhibitor for Metastatic Melanoma: A Case Report

by Stefano Cavalieri, Lorenza Di Guardo, Mara Cossa, Carolina Cimminiello, Michele Del Vecchio
Published 2017-07-01

Combined targeting of MEK and the glucocorticoid receptor for the treatment of RAS-mutant multiple myeloma

by Priya Sriskandarajah, Alexis De Haven Brandon, Kenneth MacLeod, Neil O. Carragher, Vladimir Kirkin, Martin Kaiser, Steven R. Whittaker
Published 2020-03-01

Celecoxib as a Valuable Adjuvant in Cutaneous Melanoma Treated with Trametinib

by Diana Valentina Tudor, Ioana Bâldea, Diana Elena Olteanu, Eva Fischer-Fodor, Virag Piroska, Mihai Lupu, Tudor Călinici, Roxana Maria Decea, Gabriela Adriana Filip
Published 2021-04-01

Overall Survival of Patients With Unresectable or Metastatic BRAF V600-Mutant Acral/Cutaneous Melanoma Administered Dabrafenib Plus Trametinib: Long-Term Follow-Up of a Multicenter...

by Lili Mao, Ya Ding, Xue Bai, Xinan Sheng, Jie Dai, Zhihong Chi, Chuanliang Cui, Yan Kong, Yun Fan, Yanjun Xu, Xuan Wang, Bixia Tang, Bin Lian, Xieqiao Yan, Siming Li, Li Zhou, Xiaoting Wei, Caili Li, Jun Guo, Xiaoshi Zhang, Lu Si
Published 2021-08-01

Efficacy and Biomarker Analysis of Adavosertib in Differentiated Thyroid Cancer

by Yu-Ling Lu, Ming-Hsien Wu, Yi-Yin Lee, Ting-Chao Chou, Richard J. Wong, Shu-Fu Lin
Published 2021-07-01

Clinical Benefit from Trametinib in a Patient with Appendiceal Adenocarcinoma with a GNAS R201H Mutation

by Celina Ang, Aryeh Stollman, Hongfa Zhu, Umut Sarpel, Bethann Scarborough, Gagan Sahni, Sherri Z. Millis
Published 2017-06-01

Enhancing Therapeutic Efficacy of Oncolytic Herpes Simplex Virus with MEK Inhibitor Trametinib in Some BRAF or KRAS-Mutated Colorectal or Lung Carcinoma Models

by XuSha Zhou, Jing Zhao, Jian V. Zhang, Yinglin Wu, Lei Wang, Xiaoqing Chen, Dongmei Ji, Grace Guoying Zhou
Published 2021-09-01

Targeting SERT promotes tryptophan metabolism: mechanisms and implications in colon cancer treatment

by Di Ye, Huanji Xu, Hongwei Xia, Chenliang Zhang, Qiulin Tang, Feng Bi
Published 2021-05-01

Population Pharmacokinetics/Pharmacodynamics of Dabrafenib Plus Trametinib in Patients with BRAF-Mutated Metastatic Melanoma

by David Balakirouchenane, Sarah Guégan, Chantal Csajka, Anne Jouinot, Valentine Heidelberger, Alicja Puszkiel, Ouidad Zehou, Nihel Khoudour, Perrine Courlet, Nora Kramkimel, Coralie Lheure, Nathalie Franck, Olivier Huillard, Jennifer Arrondeau, Michel Vidal, Francois Goldwasser, Eve Maubec, Nicolas Dupin, Selim Aractingi, Monia Guidi, Benoit Blanchet
Published 2020-04-01

Ocular toxicity due to Trametinib and Dabrafenib

by Stephanie Sarny, Michael Neumayer, Julian Kofler, Yosuf El-Shabrawi
Published 2017-08-01

A Rare Case of Pituitary Melanoma Metastasis: A Dramatic and Prolonged Response to Dabrafenib-Trametinib Therapy

by Marilda Mormando, Giulia Puliani, Giulia Puliani, Agnese Barnabei, Rosa Lauretta, Marta Bianchini, Alfonsina Chiefari, Michelangelo Russillo, Francesco Cognetti, Luisa Romano, Marialuisa Appetecchia
Published 2020-07-01

EphA2-Receptor Targeted PEGylated Nanoliposomes for the Treatment of BRAF^V600E Mutated Parent- and Vemurafenib-Resistant Melanoma

by Yige Fu, Drishti Rathod, Ehab M. Abo-Ali, Vikas V. Dukhande, Ketan Patel
Published 2019-10-01

Targeting few to help hundreds: JAK, MAPK and ROCK pathways as druggable targets in atypical chronic myeloid leukemia

by Stefania Rocca, Giovanna Carrà, Pietro Poggio, Alessandro Morotti, Mara Brancaccio
Published 2018-02-01

The oncogene KRAS promotes cancer cell dissemination by stabilizing spheroid formation via the MEK pathway

by Juri Ogishima, Ayumi Taguchi, Akira Kawata, Kei Kawana, Mitsuyo Yoshida, Yuki Yoshimatsu, Masakazu Sato, Hiroe Nakamura, Yoshiko Kawata, Akira Nishijima, Asaha Fujimoto, Kensuke Tomio, Katsuyuki Adachi, Takeshi Nagamatsu, Katsutoshi Oda, Tohru Kiyono, Yutaka Osuga, Tomoyuki Fujii
Published 2018-12-01

Spotlight on dabrafenib/trametinib in the treatment of non-small-cell lung cancer: place in therapy

by Weart TC, Miller KD, Simone CB 2nd
Published 2018-04-01

Anti–PD-1 in Combination With Trametinib Suppresses Tumor Growth and Improves Survival of Intrahepatic Cholangiocarcinoma in MiceSummary

by Simon Wabitsch, Mayank Tandon, Benjamin Ruf, Qianfei Zhang, Justin D. McCallen, John C. McVey, Chi Ma, Benjamin L. Green, Laurence P. Diggs, Bernd Heinrich, Tim F. Greten
Published 2021-01-01